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Abstract—Multiple Sclerosis (MS) is a demyelinating dis-
ease which causes inflammation, demyelination, and axonal
injury. Currently, there is no cure for the disease. The endo-
cannabinoid system has recently emerged as a promising
therapeutic target for MS. The protective mechanisms of
cannabinoids are thought to be mediated by the activation
of the cannabinoid type 1 (CB1) and type 2 (CB2) receptors
expressed primarily in neurons and immune cells,
respectively. However, the molecular mechanisms and the
contribution of each receptor in ameliorating disease
progression are still debatable. Although CB1 and CB2
receptors are expressed in oligodendrocytes, the myelin
producing cells in the central nervous system, the role of
cannabinoids in oligodendrocyte survival has not been well
investigated. Using primary cultures of mature oligodendro-
cytes, we tested the effect of a novel synthetic cannabinoid
CB52 on oligodendrocyte toxicity induced by peroxynitrite,
the primary toxic species released by microglia. Interest-
ingly, we found that CB52 is more potent than a number of
broad and selective CB1 and CB2 agonists in protecting oli-
godendrocytes against peroxynitrite-induced toxicity. The
protection provided by CB52 is likely due to its reduction
of ERK1/2 phosphorylation and reactive oxygen species
(ROS) generation in these cells. Using experimental
autoimmune encephalomyelitis (EAE), an animal model of
MS, we found that CB52 reduces microglia activation,
nitrotyrosine formation, T cell infiltration, oligodendrocyte
toxicity, myelin loss and axonal damage in the mouse spinal
cord white matter and alleviates the clinical scores when
given either before or after disease onset. These effects
are reversed by the CB1 receptor antagonist, but not by
the CB2 receptor antagonist, suggesting that the activation
of CB1 receptors contributes significantly to the anti-inflam-
matory and neuroprotective effects of cannabinoids on MS.
Published by Elsevier Ltd. on behalf of IBRO.
Key words: cannabinoid, experimental autoimmune
encephalomyelitis, oligodendrocyte, myelination, microglia,
T cells.
INTRODUCTION
MultipleSclerosis (MS) is anautoimmune diseaseaffecting
the central nervous system (CNS). It is the most common
demyelinating disease in young adults and results in
motor and sensory deficits (Polman and Uitdehaag,
2000). MS is characterized by chronic inflammation
resulting from the infiltration of T cells and the activation
of microglia/macrophages culminating in the loss of
oligodendrocytes, demyelination and axonal damage
(Pryce et al., 2003). Although no cure exists, advances in
research have led us to a better understanding of the
pathogenic mechanisms, which aid the development of
novel and effective agents for the treatment of MS.
Cannabinoids are a class of compounds being studied
for the treatment of MS and other neurological diseases
(Baker et al., 2000; Arevalo-Martin et al., 2003;
Lastres-Becker et al., 2004; Venderova´ et al., 2004;
Eubanks et al., 2006; Sagredo et al., 2007; van Vliet
et al., 2008). Preclinical and clinical studies have
demonstrated that cannabinoids can alleviate MS
symptoms due to their anti-inflammatory (Arevalo-Martin
et al., 2003), antioxidant (Howlett et al., 2002), and anti-
excitotoxic properties (Grundy et al., 2001; Pryce et al.,
2003). Cannabinoids have been shown to be protective
to oligodendrocytes, the myelinating cells of the CNS, by
promoting the survival and differentiation of progenitor
oligodendrocytes in vitro (Molina-Holgado et al., 2002)
and in vivo (Solbrig et al., 2010). Thus, cannabinoids can
be potentially used as effective agents in limiting
demyelination and promoting remyelination.
Experimental autoimmune encephalomyelitis (EAE)
is a commonly used animal model that mimics the
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symptoms of MS in humans (Baker et al., 1990; Wujek
et al., 2002). The first study using cannabinoids in this
model system showed that D9-tetrahydrocannabinol
(THC), the main active component of the cannabis
plant, has immunomodulatory functions, as indicated by
the reduced numbers of infiltrating cells in the spinal
cord (Lyman et al., 1989). Following this study many
groups have further demonstrated the beneficial effects
of various cannabinoids in different animal models of
MS (Kubajewska and Constantinescu, 2010). The
beneficial effects of cannabinoids are attributable to
their activation of cannabinoid type 1 (CB1) and CB2
receptors (Matsuda et al., 1990; Munro et al., 1993),
although increasing evidence points to the contribution
by novel receptors and receptor-independent
mechanisms (Puffenbarger et al., 2000; Kaplan et al.,
2003, 2008; Walter et al., 2003; Kozela et al., 2010).
Studies using knockout animals showed that a
deficiency in either CB1 (Pryce et al., 2003) or CB2
(Palazuelos et al., 2008) receptors resulted in more
severe EAE. The regulatory action of cannabinoids in
EAE-induced neurodegeneration is largely due to CB2
receptor-mediated modulation of the immune and
inflammatory response and CB1 receptor-mediated
neuroprotection (Maresz et al., 2007), although the
relative contribution of each receptor might be
dependent upon the specific cannabinoid compounds
applied. Because activation of CB1 receptors can
produce psychotropic effects, current efforts are
focused on searching for agents that increase the
therapeutic efficacy and meanwhile reduce the side
effects.
CB52 is a novel cannabinoid compound synthesized
on the basis of the structural modification of the
endocannabinoid ligand anandamide (AEA) and the
phytocannabinoid D9-THC. This compound was shown
to exhibit high affinity for the central CB1 and peripheral
CB2 receptors with Ki values of 210 and 30 nM,
respectively (Brizzi et al., 2005). We have recently
reported that like other non-selective, as well as
selective CB1 and CB2 agonists, CB52 can significantly
reduce the induction of inducible nitric oxide synthase
(iNOS) and the generation of reactive oxygen species
(ROS) in lipopolysaccharide-activated microglia.
However, the anti-inflammatory effects seem not to be
mediated by the activation of CB1 and CB2 receptors
(Ribeiro et al., 2013). In the present study we tested
whether CB52 was protective against oligodendrocyte
toxicity induced by peroxynitrite, a reaction product of
nitric oxide and superoxide, and a major toxic factor
released by activated microglia (Xie et al., 2002; Li
et al., 2005). Interestingly, our results demonstrated that
CB52 is more potent and less toxic than a number of
cannabinoid receptor agonists in protecting
oligodendrocytes from peroxynitrite-induced toxicity.
Moreover, we also found that CB52 reduced
neuroinflammation, oligodendrocyte injury, myelin loss
and the clinical scores in mice with EAE. Surprisingly,
different from the results found in vitro, the therapeutic
effect of CB52 in vivo seems to be mediated by the
activation of CB1 receptors.
EXPERIMENTAL PROCEDURES
Materials
Non-selective CB1 and CB2 receptor agonists CB52,
CP55940 and AEA were from Cayman Chemicals (Ann
Arbor, MI, USA); WIN55212-2 was obtained from
Sigma–Aldrich (St. Louis, MO, USA). CB1 selective
agonists ACPA, ACEA, and methanandamide were
purchased from Tocris (Ellisville, MO, USA). CB2
selective agonists AM1241 and JWH015 were from
Cayman Chemicals. CB1 antagonist AM281 was from
Tocris and CB2 antagonist AM630 was from Cayman
Chemicals. The peroxynitrite generator SIN-1 was from
Cayman Chemicals. ZnCl2 and lipopolysaccharide (LPS)
were purchased from Sigma. Animal studies were
performed according to the guidelines established by
the Uniformed Services University of the Health
Sciences and the National Research Council’s Guide for
the care and Use of Laboratory Animals.
Oligodendrocyte cell culture
Primary cultures of oligodendrocytes were prepared from
2- to 3-day-old Sprague–Dawley rat brain. Cultures were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 20% heat-inactivated fetal bovine
serum and 1% penicillin/streptomycin in 75 cm2 flasks
incubated in 95% air/5% CO2 at 37 C. At 10 days, the
flasks were shaken for 1 h on an orbital shaker
(200 rpm) at 37 C to remove microglia. They were then
changed to new media and shaken overnight.
Oligodendrocytes were harvested and seeded onto poly-
ornithine-coated plates [96-well (2.3  106 cells/plate),
24-well (3  106 cells/plate)] in a basal chemically-
defined medium (BDM) [DMEM with 1 mg/ml bovine
serum albumin (BSA), 50 lg/ml apo-transferrin, 5 lg/ml
insulin, 30 nM sodium selenite, 10 nM biotin, 10 nM
hydrocortisone] plus 10 ng/ml of both platelet-derived
growth factor (PDGF) and basic fibroblast growth factor
(bFGF). For culturing mature oligodendrocytes, cells at
day 7 were changed to BDM plus T3 (15 nM) and ciliary
neurotrophic factor (CNTF) (10 ng/ml) for another
2 weeks. This results in a culture where the purity of
oligodendrocytes is more than 95%, and only 1–2% of
cells are identified to be either microglia or astrocytes as
described previously (Li et al., 2012).
Exposure of oligodendrocytes to cannabinoids and
SIN-1 or zinc
In each experiment, cannabinoid agonists were added
30 min prior to 3-morpholinosydnonimine (SIN-1) or zinc
chloride (ZnCl2) exposure and maintained during the
treatment. When used, antagonists were added 15 min
prior to agonists. All compounds were dissolved in 0.1%
dimethyl sulfoxide (DMSO), which was used as the
vehicle control.
Toxicity assay
Oligodendrocytes were treated with SIN-1 or zinc in the
presence or absence of cannabinoids for 2 h, washed
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twice with Hank’s balanced salt solution (HBSS)
containing 0.1% BSA, and then placed in BDM with T3
and CNTF. After the cells were incubated for 20–24 h,
the culture medium was replaced with Earle’s balanced
salt solution (EBSS) plus a 1:100 dilution of Alamar Blue
(Trek Diagnostic Systems, Inc., Westlake, OH, USA).
After 2 h exposure, the cell viability was assessed using
a fluorescent plate reader (SpectraMax Gemini XS, GMI
Inc., MN, USA) with excitation wavelength at 530 nm
and emission wavelength at 590 nm.
Western blot analysis
At 2 h after SIN-1 or zinc treatment, oligodendrocytes
were lysed and the protein concentration in lysates was
measured. After the sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE), the
membrane was blocked with 5% nonfat milk for 1 h and
then incubated overnight at 4 C with the primary
antibody for phosphorylated ERK42/44 or total ERK42/
44 (Cell Signaling, Beverly, MA, USA) diluted at 1:2000
in Tris-buffered saline and Tween 20 (TBST) containing
5% BSA. After washing, the membrane was incubated
for 1 h at room temperature (RT) with a horseradish
peroxidase (HRP)-conjugated anti-rabbit secondary
antibody diluted at 1:2000. The proteins were visualized
by enhanced chemiluminescence (ECL). Quantification
for Western blot analysis was done by measuring band
density using Multi Gauge software.
Measurement for ROS
Intracellular free radical generation was evaluated with
20,70-dichlorohydrofluorescein diacetate (DCF; Molecular
Probes, Eugene, OR, USA). Briefly, after the cells in
96-well plates were treated with SIN-1 or zinc with/
without cannabinoids for 2 h, they were loaded with
DCF (10 lM) for 30 min. The fluorescence of the cells in
each well was measured using a fluorescence plate
reader with excitation wavelength at 480 nm and
emission wavelength at 530 nm.
Induction of EAE
EAE was induced in 7-week-old female C57BL/6 mice
(Jackson Labs, Bar Harbor, ME, USA) as we previously
described (Li et al., 2011; Vana et al., 2011). EAE was
induced by subcutaneous injection of 200 lg myelin
oligodendrocyte glycoprotein (MOG) peptide 35–55
(H-MEVGWYRSPFSRVVHLYRNGK-OH) in Complete
Freunds Adjuvant (CFA, DIFCO, Detroit, MI, USA) with
500 lg mycobacterium tuberculosis (DIFCO).
Immediately following MOG peptide injection and 24 h
later mice were intraperitoneally (i.p.) administered
200 lg pertussis toxin (List Biological Labs, Campbell,
CA, USA). At 1 week after induction EAE mice received
a booster of 200 lg of MOG in incomplete Freunds
Adjuvant without mycobacterium tuberculosis. Animals
in the control group received pertussis toxin and CFA
without the MOG peptide. Mice were assessed daily to
evaluate the extent of dysfunction following EAE
induction. Neurological signs were assessed as follows:
0, normal; 1, dysfunction of tail or one limb; 2,
dysfunction of tail and one limb or two limbs; 3, limp tail
and dysfunction of two limbs; 4, disturbed function in tail
and three limbs or dysfunction of all limbs; 5, moribund;
6, death.
Immunohistochemistry (IHC)
Animals were euthanized using 90-mg ketamine/10-mg
xylazine per kg, i.p., then intracardially perfused with
ice-cold 1 M phosphate buffer. Spinal cords were
dissected prior to post-fixation in 4% paraformaldehyde
at 4 C overnight. Tissue was then cryoprotected in 30%
sucrose (Sigma) in 1 M phosphate buffer at 4 C
overnight. After being cryoprotected the tissue was
embedded in Tissue Tek OCT (Sakura, Torrance, CA,
USA) and stored at 80 C until utilization. Transverse
sections of lumbar spinal cords were cut at 14 lm with
a cryostat (Leica model CM1900, Bannockburn, IL,
USA) and mounted onto Superfrost Plus slides (Fisher,
Pittsburgh, PA, USA) for immunohistological analysis.
Slides were washed three times with phosphate-
buffered solution (PBS), and blocked with 1% Triton
X-100 in PBS containing 5% donkey serum for 20 min
at room temperature. The slides were then incubated
with the appropriate primary antibody diluted in PBS
containing 2% donkey serum. Primary antibodies used
were for: Microglia/Macrophages marker F4/80 (1:100,
eBioscience, San Diego, CA, USA); Nitrotyrosine, a
marker for peroxynitrite formation (1:100, Chemicon,
Temecula, CA, USA); CC1, a marker for mature
oligodendrocyte (1:100, Calbiochem, Germany); CD4
T-lymphocytes (1:100, BD Pharmingen, San Diego, CA,
USA) and NF200 (1:250, Millipore, Burlington, MA,
USA), a marker for axons. Primary antibodies were
incubated overnight at 4 C. After three washes with
PBS at 5 min each, the appropriate secondary antibody
conjugated with either Alexia Fluor 488 or Alexia Fluor
594 (Molecular Probes) was added and then incubated
for 1 h at room temperature. After three washes with
PBS, the slides were mounted with Fluoro Shield
together with 4’,6-Diamidino-2-Phenylindole (DAPI,
Sigma) and kept dark at 4 C. Images were captured
with a fluorescence microscope (Nikon Eclipse E800)
equipped with a Nikon digital camera. For tumor
necrosis factor-a (TNF-a) staining, the slides were
rinsed in PBS and incubated in PBS containing 0.3%
Triton and a polyclonal anti-TNF-a antibody (Abcam,
Cambridge, MA, USA) at 4 C overnight. After washing
three times with 5 min each, the slides were incubated
with a biotinylated secondary antibody for 30 min. The
sections were washed for 5 min and then incubated for
30 min with Vectastain ABC reagent (Vector
Laboratories, Inc., Burlingame, CA, USA). After another
5 min washing, the sections were incubated in
peroxidase substrate solution until desired staining
intensity developed. Cells counts were performed in the
white matter of the spinal cord using NIS-Elements
software (Nikon, Melville, NY, USA). Three sections per
animal were counted and the average was recorded.
The number of individual animals (n) is indicated in the
figure legends.
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Oil Red O staining
To perform Oil Red O staining, frozen tissues were
sectioned at 14-lm thickness with a cryostat (Leica,
Bannockburn, IL, USA) and mounted on slides. The
slides were air dried for 60 min at room temperature and
then placed in absolute propylene glycol for 5 min. The
sections were further incubated in pre-warmed Oil Red
O solution for 10 min in 60 C water bath and followed
by differentiation in 85% propylene glycol solution for
5 min. Finally the section were mounted with
VectaMount (Vector, CA, USA) aqueous mounting
medium and visualized with a Zeiss (Oberkochen,
Germany) Axioplan 2ie microscope.
Statistical analysis
Statistical significance was assessed using analysis of
variance (ANOVA) with the Tukey–Kramer post hoc
multiple comparison test. Statistical analysis was
performed using the Instat program from GraphPad
Software (San Diego, CA, USA). Representative
experiments are shown unless noted otherwise.
Experiments were performed with triplicate samples,
and the data are expressed as mean ± SEM. All
experiments were repeated at least three times.
RESULTS
Cannabinoids protect mature oligodendrocytes
against peroxynitrite- and zinc-induced toxicity
Although both CB1 and CB2 receptors are expressed in
various stages of oligodendrocytes, it is unclear whether
the activation of these receptors can prevent oxidative
injury to mature, myelin producing, oligodendrocytes.
Using a novel cannabinoid agent CB52, and three
commonly used non-selective CB1/CB2 receptor
agonists CP55940, WIN55212-2 and AEA, we examined
the role of these cannabinoid compounds on
oligodendrocyte toxicity induced by SIN-1, a
peroxynitrite generator. As shown in Fig. 1, all four
cannabinoids dose-dependently protected mature
oligodendrocytes against SIN-1 induced toxicity.
However, both CP55940 and AEA were themselves
toxic at 10 lM (Fig. 1B, D), whereas CB52 (10 lM) and
WIN55212-2 (10 lM) did not have any toxicity. Notably,
a complete protection was achieved when CB52 was
used at 10 lM (Fig. 1A).
We have previously found that peroxynitrite toxicity to
mature oligodendrocytes is mediated by intracellular zinc
release, ERK1/2 phosphorylation and ROS generation
(Zhang et al., 2006, 2007). Thus, we also tested
whether these cannabinoids could prevent mature
oligodendrocytes from zinc-induced toxicity. AEA
(3 lM), WIN 55212-2 (10 lM) and CB52 (10 lM)
significantly attenuated oligodendrocyte toxicity induced
by zinc chloride (ZnCl2) at 150 lM. When 200 lM ZnCl2
was used, only CB52, but not WIN 55212-2 or AEA,
was shown to have protective effects (Fig. 1E). These
results suggest that CB52 is more potent than AEA and
WIN 55212-2 to prevent oligodendrocytes from
peroxynitrite- or zinc-induced toxicity.
Cannabinoid agonists attenuate ERK1/2
phosphorylation and ROS generation in
oligodendrocytes treated with SIN-1 or zinc
To further characterize the protective mechanisms of
cannabinoids on oligodendrocytes, the phosphorylation
of ERK1/2 induced by SIN-1 or zinc was assessed by
Western blot analysis. We found that after a 2-h
exposure to either SIN-1 (Fig. 2A) or zinc (Fig. 2B), only
CB52 was able to significantly attenuate ERK1/2
phosphorylation. All four cannabinoids tested
significantly attenuated ROS generation at 6 h after SIN-
1 treatment. A complete reduction of ROS was
observed in the presence of CB52 and CP55940,
whereas the reduction of ROS by WIN55212-2 and AEA
was 30% and 40%, respectively (Fig. 2C). CB52 was
also more effective than WIN55212-2 and AEA in
attenuating ROS generation caused by zinc (data not
shown).
Cannabinoids protect mature oligodendrocytes
against peroxynitrite and zinc toxicity through a
mechanism that is partially mediated by the CB2
receptor
Considering its high potency, we decided to focus our
studies on the protective effects of CB52 on mature
oligodendrocytes. To determine if the effect seen with
CB52 was mediated by the activation of CB1 and/or
CB2 receptors, the CB1 antagonist AM281 (10 lM) and
the CB2 antagonist AM630 (10 lM) either alone or in
combination were added 15 min prior to CB52
treatment. As shown in Fig. 3A, the protective effect of
CB52 was partially, but significantly attenuated by
AM630, but not by AM281. Addition of AM281 did not
further enhance the blocking effects exerted by AM630
suggesting the activation of CB2, but not CB1 receptor
is responsible for part of the protective effects of this
compound. Notably, the antagonists themselves did not
have any protective effect. To further test the role of
CB2 receptor in the survival of oligodendrocytes,
oligodendrocytes were treated with SIN-1 in the
presence of CB1 or CB2 receptor selective agonists.
The CB2 selective agonists AM1241 and JWH015
significantly attenuated SIN-1 induced toxicity, but
interestingly the CB1 selective agonists ACPA, ACEA
and methanandamide did not have any effect (Fig. 3B).
Similarly, the protective effect of CB52 on zinc-induced
toxicity was also partially mediated by the activation of
CB2 receptor (Fig. 3C), and the selective CB2 agonists,
but not CB1 agonists also exerted a protective effect
(Fig. 3D). Taken together, these results suggest that the
protective effect of CB52 to mature oligodendrocytes on
peroxynitrite- and zinc-induced toxicity is most likely
mediated by the CB2 receptor activation.
CB52 is protective in the EAE mouse model when
given before or after symptom development and its
effects are mediated by CB1 receptor activation
Given the findings from the in vitro studies that CB52
seems to be more effective than other commonly used
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cannabinoids in attenuating oligodendrocyte cell death
and the evidence that this effect is mediated by the CB2
receptor, we decided to test the role and the
cannabinoid receptor dependency of CB52 in EAE, a
mouse model of MS. In the first set of experiments
(Fig. 4A), mice were treated with CB52 (2 mg/kg body
weight, i.p.) in the absence or presence of the CB1
antagonist AM281 (2 mg/kg) or the CB2 antagonist
AM630 (2 mg/kg) starting at day 3 after MOG injection
and then once a day until day 30. Without treatment,
the clinical symptoms developed on day 10, and rapidly
reached clinical scores 3.0–3.5 from day 16 to day 30.
After CB52 treatment, there was a slight delay in the
disease onset, but the clinical scores were significantly
reduced from day 13 until the end of the experimental
period. In this group the maximal clinical score was 1.5,
which is dramatically reduced when compared to the
untreated EAE group (clinical score of 3.5). Surprisingly,
the reduction of clinical scores by CB52 was eliminated
by co-administration of AM281, but not AM630,
suggesting the activation of CB1 receptor contributes to
the therapeutic effect of CB52, which is distinct from our
observations in oligodendrocytes in culture.
To be more clinically relevant, we also performed the
CB52 treatment immediately after the disease onset
(Fig. 4B). Mice were administered CB52 (2 mg/kg, i.p.)
with/without AM281 or AM630 starting from day 12 and
then once daily afterward. Again, the EAE mice reached
and maintained a high clinical score of 3.0 from day 16
to day 30, post-symptom treatment with CB52
significantly reduced clinical scores starting from day 17,
and further reduction was seen until the end of the
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Fig. 1. The non-selective cannabinoid agonists CB52, CP55940, WIN55212, and AEA protected SIN-1- and zinc-induced toxicity to mature
oligodendrocytes. Primary oligodendrocytes were exposed to SIN-1 (1 mM) for 2 h in the presence of different concentrations (10 lM–10 nM) of the
non-selective cannabinoid agonists CB52 (A), CP55940 (B), WIN55212 (C), and AEA (D) or exposed to ZnCl2 with CB52, WIN55212 and AEA
(E). While all test compounds can attenuate SIN-1 toxicity in mature oligodendrocytes, CB52 (A, E) showed a better effect when compared with the
other cannabinoid agonists (n= 5–9; ⁄p< 0.05, ⁄⁄p< 0.01, and ⁄⁄⁄p< 0.001 were obtained when the drug-treated groups were compared to the
SIN-1 or zinc-alone group).
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experiment. The reduction of CB52 on clinical scores was
completely eliminated by co-treatment with AM281, but
not AM630, although co-administration of AM630
seemed to partially reverse the clinical scores. These
results clearly indicate that CB1 receptor activation
plays a dominant role for the action of CB52 in the EAE
mouse model.
In the third set of experiment (Fig. 4C) we were
interested in determining whether continuous activation
of the cannabinoid receptor is necessary for the
therapeutic action of CB52. To test this idea, animals
started receiving CB52 after symptom development at
day 12, followed by co-administration of the CB1 or
CB2 antagonist beginning at day 20. Our hypothesis
was that if transient receptor activation or short-term
treatment with CB52 is sufficient to trigger the signaling
pathway leading to protection, delayed treatment with
antagonists should not affect the action of CB52; On
the contrary, if continuous activation of cannabinoid
receptor is necessary, delayed treatment with
antagonists may still reverse the protective effect of
this cannabinoid compound. This study found that
delayed administration of CB1 antagonist, but not CB2
antagonist was likely to reverse the protective effect of
CB52, suggesting chronic treatment might be important
for sustaining the CB1 receptor signaling and
maintaining the protective effect of this cannabinoid
compound.
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Fig. 2. Cannabinoid agonists decreased ERK1/2 phosphorylation and ROS generation in oligodendrocytes treated with SIN-1 or zinc. (A) Mature
oligodendrocytes were treated with SIN-1 (1 mM) for 2 h in the presence of different concentrations of non-selective cannabinoid agonists and lysed
for Western blot analysis. Although most cannabinoids seem to reduce the ERK1/2 phophorylation, the significance was only achieved by the CB52
treatment. (n= 3; ⁄p< 0.05 was obtained when the CB52-treated group was compared to the SIN-1-alone group). (B) Mature oligodendrocytes
were treated with zinc (200 lM) for 2 h in the presence of various non-selective cannabinoid agonists and lysed for Western blot analysis. While all
three cannabinoids tested were able to decrease ERK1/2 phosphorylation in these cells, CB52 was showed to have a greater effect when compared
to WIN and AEA (n= 3; ⁄p< 0.05 was obtained when the CB52-treated group was compared to the zinc-alone group). (C) Mature
oligodendrocytes were treated with SIN-1 (1 mM) for 6 h in the presence of different concentrations of non-selective cannabinoid agonists and then
incubated with DCF for 30 min. The increased fluorescent intensity, indicative of ROS generation, was then measured. While all drugs tested were
able to attenuate ROS production, a complete inhibition of ROS generation was shown with CB52 and CP55940 (n= 5; ⁄⁄⁄p< 0.001 was obtained
when the drug-treated groups were compared to the SIN-1-alone group).
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CB52 attenuates accumulation of microglia/
macrophages and peroxynitrite production in the
mouse EAE spinal cord
On day 30 after EAE induction, animals were perfused
with 4% paraformaldehyde and spinal cords were
dissected and sectioned for IHC. Fig. 5 shows
representative images of microglia/macrophages by
F4/80 and the staining of nitrotyrosine, a marker for
peroxynitrite formation, in the spinal cord dorsal
columns in our first set of experimental groups (i.e.
animals that received CB52 with/without antagonists
starting from day 3 after induction). Our results showed
that there was a dramatic increase in the staining of
F4/80 and nitrotyrosine in EAE animals (Fig. 5B, F, G)
compared to the control animals without EAE induction
(Fig. 5A, F, G). Treatment with CB52 almost completely
blocked F4/80 and nitrotyrosine staining (Fig. 5C, F, G);
indicating CB52 is effective in blocking the accumulation
of microglia/macrophages and the release of
peroxynitrite. Consistent with the effects on the clinical
scores, co-treatment with the CB1 antagonist (Fig. 5D,
F, G) but not the CB2 antagonist (Fig. 5E–G) reversed
the effects of CB52. Similar results were also observed
with post-symptom treatment by CB52 at day 12
together with the CB1 and CB2 antagonists and when
antagonist treatment was delayed until day 20 (data not
shown).
CB52 attenuates T cell infiltration in the spinal cords
of EAE mice
EAE is primarily mediated by the infiltration of CD4+ T
lymphocytes from the periphery to the CNS, and once in
the CNS, these T cells can be activated by local antigen
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antagonist AM630. Toxicity was then evaluated using Alamar Blue. CB52 is able to attenuate SIN-1 toxicity in mature oligdendrocytes and this effect
was partially blocked in the presence of the CB2 antagonist but not the CB1 antagonist (n= 5; ⁄⁄p< 0.01, and ⁄⁄⁄p< 0.001). (B) Mature
oligodendrocytes were treated with SIN-1 (1 mM) for 2 h in the presence of the CB1 selective agonists ACPA, ACEA and methanandamide and the
CB2 selective agonists AM1241 and JWH015. Toxicity was then evaluated using Alamar Blue. The CB2 agonists but not the CB1 agonists were
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the CB1 agonists were able to partially attenuate zinc toxicity to mature oligodendrocytes. (n= 5; ⁄⁄⁄p< 0.001 and ###p< 0.001).
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presenting cells and release inflammatory mediators
(Kubajewska and Constantinescu, 2010). At 30 days
after EAE induction, the infiltration of CD4+ T cells was
clearly observed in the spinal cord white matter, which
was almost completely blocked by treatment with CB52
either before (Fig. 6A, B) or after (Fig. 6C, D) symptom
development. Interestingly, the blocking effect of T cell
infiltration by CB52 was also reversed by the co- or
delayed-administration of CB1 antagonist AM281, but
not the CB2 antagonist AM630 (Fig. 6A–D). These
results suggest that CB52 can block T cell infiltration
through the activation of CB1 receptors.
CB52 reduces TNF-a production in EAE spinal cord
white matter
TNF-a is one of the major cytokines released from CD4+
T cells and reactive microglia/macrophages, and believed
to contribute to the pathogenesis of EAE and MS (Hofman
et al., 1989; Selmaj et al., 1991). To determine whether
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CB52 can reduce the production of TNF-a in EAE mouse
spinal cord, the spinal cord sections from control, EAE
vehicle and drug-treated EAE groups at 30 days after
EAE induction were subjected to immunohistochemical
analysis to examine the production of TNF-a in the
white matter. The immunoreactivity of TNF-a was
dramatically increased in EAE mouse spinal cord when
compared to the control animals. Treatment with CB52
significantly reduced TNF-a expression, and this
reduction was reversed by co-administration of CB1
receptor antagonist AM281, but not by the CB2 receptor
antagonist AM630 (Fig. 7A, B).
CB52 prevents oligodendrocyte cell loss and
demyelination in the spinal cords of EAE mice
Oligodendrocyte cell death and demyelination are two
major components in MS and EAE (Bjartmar et al.,
2003; Furlan et al., 2009; Lassmann, 2010). Using CC1,
a marker for mature oligodendrocytes, we examined
whether CB52 treatment can affect the survival of
oligodendrocytes (Fig. 8A). As demonstrated previously,
the number of CC1-positive cells in the spinal cord white
matter is significantly reduced in EAE animals when
compared to controls (Li et al., 2011; Vana et al., 2011).
As anticipated, CB52 is effective in preventing the loss
of these cells in the spinal cord white matter when given
before (Fig. 8A) or after (Fig. 8B, C) symptom
development. Contrary to our in vitro studies, however,
we found that blocking the CB1, but not the CB2
receptor reversed the protective effect of CB52 no
matter the antagonists were given at day 3 (Fig. 8A) or
day 12 (Fig. 8B). Delayed administration of CB1
antagonist AM281 seemed also to reduce the protective
effect of CB52, although this reduction did not reach
significance when compared to the CB52-alone-treated
group (Fig. 8C).
We then looked at demyelination by staining the spinal
cord sections with Oil Red O. In these sections myelin
staining appears to be red, and the white or bleached
areas in the white matter are indicative of demyelination
(Fig. 9A). Consistent with the loss of mature
oligodendrocytes, demyelination was greater in EAE
animals when compared to control animals, and CB52
was very effective in preventing demyelination when
given 3 days (Fig. 9A, B) or 12 days (Fig. 9C, D) after
induction. The reduction of demyelination was also
blocked by the CB1 antagonist, but not by the CB2
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Fig. 5. A significant increase of microglia/macrophages and peroxynitrite formation was found in the spinal cord white matter of EAE mice, and
attenuated in the CB52-treated groups. Lumbar spinal cord sections of EAE animals treated with CB52 and the CB1/CB2 antagonists starting at day
3 post induction were stained for microglia/macrophages and nitrotyrosine (NT) immunoreactivity, which is indicative of peroxynitrite formation. EAE
animals showed increased staining for microglia/macrophages and peroxynitrite formation (B) when compared to control animals (A). Treatment
with CB52 significantly attenuated the accumulation of microglia/macrophages and reduced the nitrotyrosine formation in these animals (C). This
effect was blocked when animals were treated together with the CB1 antagonist AM281 (D), but not the CB2 antagonist AM630 (E). Quantification of
F4/80-positive (F) and NT-positive cells (G) showed that AM281, but not AM630 could reverse the inhibitory effects of CB52 (n= 3; ⁄p< 0.05, and
⁄⁄p< 0.01).
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antagonist regardless if the antagonists were given
starting from day 3 (Fig. 9A, B), day 12 (Fig. 9C) or day
20 (Fig. 9D).
CB52 prevents axonal injury in the EAE spinal cord
white matter
We also studied the effect of CB52 on axonal injury by
staining spinal cord sections with an axonal marker
NF200. In EAE animals, there was a dramatic
decrease in the levels of NF200+ staining (Fig. 10A),
indicating that axonal damage occurred in these
animals. Treatment with CB52 either before (Fig. 10A,
B) or after (Fig. 10C, D) symptom development
significantly reduced the loss of NF200+ axons.
Co-administration of AM281 appeared to attenuate the
protective effect of CB52 on axonal loss (Fig. 10A–D),
although the significant difference was only observed
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in the post-symptom treatment groups (Fig. 10C, D).
Once again, the contribution of CB2 receptor in the
action of CB52 is quite limited, if there is any.
DISCUSSION
Accumulating evidence points to the therapeutic
potential of cannabinoids in inflammatory and
neurodegenerative diseases, such as MS (Pryce and
Baker, 2012). In addition to ameliorating the clinical
symptoms in animal models (Baker and Pryce, 2008)
and MS patients (Rog, 2010), cannabinoids are also
being recognized for their ability to control disease
progression (de Lago et al., 2010). Although much
progress has been achieved over the last several
decades, questions still remain regarding the protective
mechanisms of various cannabinoids and the
involvement of CB1 and CB2 receptors. In this study
we examined the role of various cannabinoids on
mature oligodendrocyte toxicity induced by
peroxynitrite, and found that CB2 agonists, but not
CB1 agonists, have significant protective effects.
Furthermore, we found that CB52, a newly developed
AEA and D9-THC hybrid, is more effective than other
commonly used cannabinoids and its protection on
oligodendrocytes is partially mediated by the activation
of the CB2 receptor. In the EAE mouse model, our
results showed that CB52 ameliorated clinical scores
when given either before or after symptom
development. Administration of CB52 also reduced T
cell infiltration, microglia activation and the production
of TNF-a, prevented the loss of oligodendrocytes,
demyelination, and axonal injury in the spinal cord
white matter. Surprisingly, we found that contrary to
***
**
A CON EAE
EAE/CB52 EAE/CB52
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Fig. 7. CB52 reduced TNF-a expression in spinal cord of EAE mice. At day 30 after immunization, spinal cord sections from control, EAE vehicle
and drug-treated EAE groups were subjected to immunohistochemical analysis to examine the production of TNF-a in the spinal cord white matter.
The TNF-a-positive cells were counted for statistical analysis. CB52 clearly attenuated TNF-a expression compared to EAE control group as shown
in A and B (⁄⁄p< 0.01 and ⁄⁄⁄p< 0.001). Addition of CB1 antagonist AM281 but not CB2 antagonist AM630 reversed the inhibitory effect of CB52
on TNF-a expression.
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our in vitro studies, the CB1 and not the CB2 receptors
seem to be critical for the protective effects of CB52
observed in vivo.
Cannabinoids protect mature oligodendrocytes
against peroxynitrite-induced toxicity by attenuating
ERK phosphorylation and ROS generation, and this
effect is partially mediated through CB2 receptor
activation
Oligodendrocyte cell death is one of the major
characteristics of MS and EAE. Preventing mature
oligodendrocytes from injury and/or allowing
oligodendrocyte progenitors to develop into mature,
myelin-producing oligodendrocytes is of critical
importance. Several studies have shown that
cannabinoids can promote the survival of
oligodendrocytes by reducing depolarization-evoked
calcium influx (Mato et al., 2009), and preventing
apoptosis in progenitor cells (Molina-Holgado et al.,
2002). However, it has not been reported whether
cannabinoids can prevent oxidative stress-induced
toxicity to mature oligodendrocytes. We have
previously shown that peroxynitrite, a reaction product
of nitric oxide and superoxide, is a major toxic factor
released from activated microglia and injures
oligodendrocytes via a signaling pathway involving
intracellular zinc release, ERK phosphorylation and
ROS generation (Zhang et al., 2006, 2007). Here, we
were able to show that cannabinoids can directly affect
the survival of primary mature oligodendrocytes when
exposed to peroxynitrite or extracellular zinc, and that
the protection is likely attributable to their inhibition of
ERK phosphorylation and ROS generation. In
agreement to the reports by others (Molina-Holgado
et al., 2002; Benito et al., 2007), we also found that
the CB1 and CB2 receptors are expressed in
oligodendrocytes by real-time polymerase chain
reaction (PCR) and Western blot (data not shown).
However, their role in these cells remains unclear. Our
results suggest that activation of CB2 receptor, but not
CB1 receptor, might be responsible for the protective
effect of CB52 and other cannabinoid agents on
oxidative stress-induced toxicity. These results inspired
us to test the therapeutic efficacy of CB52 in vivo,
considering the notion that CB2 receptor activation
does not cause psychotropic side effects.
Co
ntr
ol
EA
E
CB
52
/EA
E
CB
52
+2
81
/EA
E
CB
52
+6
30
/EA
E
0
200
400
600
800
1000
**
**
*
Day 3
C
C
1
(c
el
ls
/m
m
2 )
Control EAE
CB52/EAE CB52+281/EAE CB52+630/EAE
Co
ntr
ol
EA
E
CB
52
/EA
E
CB
52
+2
81
/EA
E
CB
52
+6
30
/EA
E
0
200
400
600
800
1000 ** *
Day 12
C
C
1
(c
el
ls
/m
m
2 )
A 
B 
0
200
400
600
800
1000 * *
Day 20
C
C
1
(c
el
ls
/m
m
2 )
C 
Co
ntr
ol
EA
E
CB
52
/EA
E
CB
52
+2
81
/EA
E
CB
52
+6
30
/EA
E
Fig. 8. CB52 prevented the loss of mature oligodendrocytes in the spinal cords of EAE animals. (A) At 30 days post immunization, the density of
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oligodendrocytes was prevented by treatment with CB52 at day 3 post- induction. This effect was blocked by the CB1 antagonist (AM281), but not
the CB2 antagonist (AM630). (n= 4; ⁄p< 0.05, and ⁄⁄p< 0.01). (B, C) CB52 was also effective in preventing the loss of mature oligodendrocytes
when given after symptom development (B, C), and this effect was blocked when the CB1 antagonist was given at 12 days post induction (B), but
not at 21 days post induction, although a similar trend was also observed (C). (n= 5; ⁄p< 0.05).
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CB52 is effective in lowering clinical scores in EAE
animals when given either before or after symptom
development
EAE is a well-described and commonly used animal
model for MS. Its pathological and clinical features are
similar to those seen in patients, including the
inflammatory components leading to demyelination and
neurological dysfunction (Lavi and Constantinescu,
2005; Baxter, 2007). Using this model, we found that
CB52 can reduce clinical symptoms when given either
before (3 days after MOG immunization) or after
disease onset (12 days after MOG immunization when
the symptoms became apparent). When EAE animals
were treated together with the CB1 and CB2
antagonists, we found that blocking the CB1 but not the
CB2 receptor reversed the reduction of clinical scores,
suggesting the action of CB52 is mediated through the
activation of CB1 receptors. Although this result is
consistent with a recent study indicating that the
protective effect of a non-selective CB1/CB2 agonist
WIN55212-2 is mediated by CB1, but not CB2 activation
in the EAE mouse model, we were surprised by our
findings since the protective effect of CB52 against
peroxynitrite- or zinc-induced toxicity is partially
mediated by CB2 receptor in cultured oligodendrocytes
and the notion that modulation of CB2 receptor may be
more relevant for controlling the immune-aspects of the
disease (Maresz et al., 2007; Palazuelos et al., 2008;
Rossi et al., 2010).
CB52 treatment reduces inflammation,
oligodendrocyte toxicity, demyelination and axonal
loss via CB1 receptor-mediated mechanisms
To further determine the role of CB52 in the pathological
changes after EAE induction and the involvement of CB1
and CB2 receptors, we assessed microglia activation, T
cell infiltration, TNF-a production, oligodendrocyte
toxicity, demyelination and axonal injury. In agreement
with the effect on clinical scores, CB52 treatment
attenuated T cell infiltration, accumulation of microglia/
macrophages, TNF-a production and the loss of mature
oligodendrocytes, myelin and axons. Again, all these
effects are mediated by the activation of CB1, rather
than CB2 receptors. These results are different from the
previous reports showing CB2-mediated inhibition of
microglia activation (Price et al., 2009; Stella, 2009) and
T cells (Maresz et al., 2007), but are in agreement with
those showing that the CB1 receptor can affect the
inflammatory response (Pryce et al., 2003; de Lago
et al., 2010). Although the results obtained by CB52
in vitro and in vivo seem to be paradoxical, several
possibilities might be taken into consideration. First, the
expression of CB1/CB2 receptors in virtually all the
immune cells, neurons and glia cells makes it difficult to
sort out the specific role of these receptors in each cell
type and the overall contribution of these receptors
in vivo; Second, although our results have demonstrated
that the protective effect of CB52 on peroxynitrite-
induced toxicity to oligodendrocytes is partially mediated
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Fig. 9. CB52 reduced myelin loss in the spinal cord of EAE animals. (A) Myelin loss was measured by staining sections of lumbar spinal cords with
Oil Red O where intact myelin can be seen as a red staining and demyelinated areas appear white. (B) CB52 treatment starting at day 3 post
induction attenuated myelin loss when compared to the EAE control animals. This effect was blocked by the CB1 antagonist (AM281), but not the
CB2 antagonist (AM630). (n= 5; ⁄⁄p< 0.01, and ⁄⁄⁄p< 0.001). (C, D) CB52 was also effective in preventing myelin loss when given after
symptom development on day 12 (C, D). This protective effect was blocked by the CB1 antagonist (AM281) when given at 12 (C) or 21 days (D) post
induction. (n= 5; ⁄p< 0.05, and ⁄⁄⁄p< 0.001).
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by CB2 receptor, it is unclear whether activation of CB1
receptor can be involved in other toxic conditions, for
instance, the toxicity triggered by cytokines, chemokines
or glutamate; Third, the CB2 receptors expressed in T
cells are highly regulated by endogenous cannabinoid
ligands in the CNS during EAE, and activation of these
receptors does not seem to require exogenous agonists
for the suppressive effects (Maresz et al., 2007;
Kubajewska and Constantinescu, 2010). This idea is
supported by a recent finding that HU-308, a CB2
receptor selective agonist, did not exact any protective
effect in EAE (de Lago et al., 2012).
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Fig. 10. Treatment with CB52 decreased axonal loss in EAE animals. (A) Axonal loss was measured by the density of NF200-positive axons in
lumbar spinal cord sections. EAE animals show decreased NF200-positive staining, which was rescued after CB52 treatment. (B) CB52 given
before symptom development (day 3) significantly decreased axonal loss caused from EAE. While no significant effect can be seen when either
antagonist was used, the CB1 antagonist seemed to be more effective in reversing the effects of CB52 (n= 4; ⁄p< 0.05 and ⁄⁄p< 0.01). (C, D)
CB52 was also effective in preventing axonal loss when given after symptom development on day 12 (C, D). This protective effect was blocked by
the CB1 antagonist (AM281) when given at 12 (C) or 21 days (D) post induction (n= 4; ⁄p< 0.05, ⁄⁄p< 0.01 and ⁄⁄⁄p< 0.001).
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Although there is a continuous argument on the
relative contribution of CB1 and CB2 receptors in the
animal models of MS, the fact that mice with either CB1
or CB2 receptor deletion developed more severe EAE
(Pryce et al., 2003; Palazuelos et al., 2008), points to
the importance of both receptors in the progression of
disease. Recently, it has been reported that the
expression of CB1 and CB2 receptors is reduced in
proteolipid protein (PLP)-induced EAE mouse brain, and
elevated by treatment with 2-arachidonoylglycerol, the
most abundant endocannabinoid in the brain,
suggesting activation of both CB1 and CB2 receptors
mediates the neuroprotection and immunosuppression
in EAE (Lourbopoulos et al., 2011). In addition, it
becomes increasingly appreciated that novel receptors
and receptor-independent mechanisms might
also contribute to the protective action of cannabinoids
(Di Marzo et al., 2000; Baskfield et al., 2004;
Garcia-Arencibia et al., 2007). Development of novel
cannabinoid compounds with increased therapeutic
efficacy and the reduced side effects will likely benefit
the patients with MS and other neurological disorders.
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